| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Neoplasms | 11 | 2023 | 101 | 1.350 |
Why?
|
| Retinoblastoma | 10 | 2023 | 112 | 1.170 |
Why?
|
| Prealbumin | 1 | 2022 | 28 | 0.750 |
Why?
|
| Ependymoglial Cells | 1 | 2022 | 10 | 0.750 |
Why?
|
| Uveal Neoplasms | 5 | 2022 | 57 | 0.710 |
Why?
|
| Giant Cell Arteritis | 5 | 2021 | 57 | 0.650 |
Why?
|
| Vitreous Body | 8 | 2023 | 96 | 0.370 |
Why?
|
| Biopsy | 11 | 2021 | 1284 | 0.360 |
Why?
|
| Temporal Arteries | 5 | 2021 | 39 | 0.360 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 61 | 0.340 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2022 | 56 | 0.330 |
Why?
|
| Orbital Diseases | 3 | 2018 | 72 | 0.310 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 1360 | 0.280 |
Why?
|
| Retina | 5 | 2022 | 490 | 0.280 |
Why?
|
| Sclera | 2 | 2018 | 41 | 0.270 |
Why?
|
| Eye Neoplasms | 2 | 2023 | 46 | 0.260 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 119 | 0.260 |
Why?
|
| Intraocular Lymphoma | 2 | 2016 | 2 | 0.250 |
Why?
|
| Melanoma | 3 | 2018 | 952 | 0.240 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2023 | 27 | 0.210 |
Why?
|
| Retinitis | 1 | 2023 | 16 | 0.200 |
Why?
|
| Eye Infections, Viral | 1 | 2023 | 28 | 0.200 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 2018 | 43 | 0.200 |
Why?
|
| Ciliary Body | 2 | 2022 | 24 | 0.200 |
Why?
|
| Eye Enucleation | 6 | 2022 | 45 | 0.190 |
Why?
|
| Fluoresceins | 1 | 2022 | 33 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1668 | 0.190 |
Why?
|
| Optic Nerve Injuries | 1 | 2022 | 11 | 0.180 |
Why?
|
| Calciphylaxis | 1 | 2021 | 4 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 2 | 2021 | 148 | 0.180 |
Why?
|
| Cataract | 1 | 2022 | 167 | 0.170 |
Why?
|
| Vasculitis | 1 | 2021 | 50 | 0.170 |
Why?
|
| Follow-Up Studies | 6 | 2023 | 5412 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 333 | 0.170 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 9 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 215 | 0.170 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2020 | 16 | 0.170 |
Why?
|
| Mucins | 1 | 2020 | 72 | 0.160 |
Why?
|
| Eye Diseases | 2 | 2016 | 116 | 0.160 |
Why?
|
| Humans | 42 | 2024 | 132064 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 142 | 0.160 |
Why?
|
| Orbit | 2 | 2017 | 84 | 0.160 |
Why?
|
| Graves Ophthalmopathy | 1 | 2019 | 16 | 0.150 |
Why?
|
| Brachytherapy | 2 | 2018 | 95 | 0.150 |
Why?
|
| Visual Acuity | 3 | 2018 | 707 | 0.150 |
Why?
|
| Orbital Pseudotumor | 2 | 2017 | 10 | 0.150 |
Why?
|
| Oculomotor Muscles | 1 | 2019 | 68 | 0.150 |
Why?
|
| Strabismus | 1 | 2019 | 54 | 0.150 |
Why?
|
| Retinal Vasculitis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 8 | 0.150 |
Why?
|
| Family | 1 | 2022 | 595 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 146 | 0.150 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 803 | 0.150 |
Why?
|
| Electroretinography | 5 | 2018 | 121 | 0.150 |
Why?
|
| Siphonaptera | 1 | 2018 | 6 | 0.150 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2018 | 38 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2016 | 145 | 0.140 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2018 | 17 | 0.140 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 1030 | 0.140 |
Why?
|
| Hemianopsia | 1 | 2018 | 24 | 0.140 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2021 | 156 | 0.140 |
Why?
|
| Retinal Vessels | 1 | 2018 | 78 | 0.140 |
Why?
|
| Ribonuclease III | 1 | 2018 | 99 | 0.140 |
Why?
|
| Sphenoid Sinus | 1 | 2017 | 11 | 0.140 |
Why?
|
| Insect Bites and Stings | 1 | 2018 | 39 | 0.140 |
Why?
|
| Aged | 18 | 2024 | 21426 | 0.140 |
Why?
|
| Carcinoma | 1 | 2020 | 300 | 0.140 |
Why?
|
| Porphyrins | 1 | 2017 | 18 | 0.140 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 82 | 0.140 |
Why?
|
| Male | 28 | 2024 | 64938 | 0.140 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2018 | 146 | 0.140 |
Why?
|
| Triamcinolone Acetonide | 2 | 2008 | 34 | 0.140 |
Why?
|
| Polychondritis, Relapsing | 1 | 2017 | 5 | 0.140 |
Why?
|
| Photochemotherapy | 1 | 2017 | 41 | 0.130 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2017 | 61 | 0.130 |
Why?
|
| Visual Fields | 1 | 2018 | 144 | 0.130 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2017 | 48 | 0.130 |
Why?
|
| Neoplasm Seeding | 1 | 2016 | 12 | 0.130 |
Why?
|
| Rabbits | 7 | 2017 | 673 | 0.130 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 218 | 0.130 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2018 | 156 | 0.130 |
Why?
|
| Middle Aged | 18 | 2020 | 28993 | 0.130 |
Why?
|
| Aspergillosis | 1 | 2016 | 46 | 0.120 |
Why?
|
| Eye Infections, Fungal | 1 | 2016 | 73 | 0.120 |
Why?
|
| Corneal Stroma | 2 | 2010 | 79 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2016 | 127 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2016 | 158 | 0.110 |
Why?
|
| Optic Nerve | 1 | 2016 | 114 | 0.110 |
Why?
|
| Papilledema | 1 | 2016 | 83 | 0.110 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 175 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 1539 | 0.110 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2013 | 6 | 0.100 |
Why?
|
| Filtering Surgery | 1 | 2013 | 4 | 0.100 |
Why?
|
| Diplopia | 1 | 2013 | 37 | 0.100 |
Why?
|
| Exotropia | 1 | 2013 | 18 | 0.100 |
Why?
|
| Silver | 1 | 2013 | 29 | 0.100 |
Why?
|
| Female | 23 | 2023 | 70664 | 0.100 |
Why?
|
| Ophthalmoplegia | 1 | 2013 | 56 | 0.100 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2013 | 12 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 67 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2013 | 56 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1340 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2023 | 6570 | 0.100 |
Why?
|
| Glaucoma | 1 | 2013 | 79 | 0.100 |
Why?
|
| Myocarditis | 1 | 2013 | 133 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 134 | 0.090 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 1957 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2018 | 3842 | 0.090 |
Why?
|
| Ophthalmic Artery | 2 | 2023 | 23 | 0.090 |
Why?
|
| Aqueous Humor | 2 | 2022 | 28 | 0.090 |
Why?
|
| Adult | 13 | 2023 | 31571 | 0.090 |
Why?
|
| Infant | 7 | 2023 | 13048 | 0.090 |
Why?
|
| Retrospective Studies | 9 | 2023 | 17389 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2022 | 664 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2057 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 7107 | 0.080 |
Why?
|
| Child, Preschool | 8 | 2022 | 14734 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1017 | 0.080 |
Why?
|
| Corneal Opacity | 1 | 2010 | 22 | 0.080 |
Why?
|
| Paraproteinemias | 1 | 2010 | 22 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 1294 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 2013 | 387 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2008 | 305 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 386 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2023 | 820 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 3 | 2008 | 1031 | 0.070 |
Why?
|
| Sirolimus | 1 | 2009 | 240 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 393 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2008 | 186 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 215 | 0.060 |
Why?
|
| Conjunctival Neoplasms | 1 | 2005 | 15 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 434 | 0.060 |
Why?
|
| Orbital Neoplasms | 1 | 2005 | 48 | 0.060 |
Why?
|
| Paraneoplastic Syndromes, Ocular | 1 | 2024 | 2 | 0.060 |
Why?
|
| Erdheim-Chester Disease | 1 | 2004 | 28 | 0.060 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2024 | 13 | 0.060 |
Why?
|
| Melanocytes | 1 | 2024 | 47 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 673 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 2 | 2018 | 490 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 308 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2023 | 13000 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 46 | 0.050 |
Why?
|
| Multimodal Imaging | 2 | 2016 | 109 | 0.050 |
Why?
|
| Ophthalmoscopy | 2 | 2017 | 34 | 0.050 |
Why?
|
| Dyspnea | 1 | 2004 | 159 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2001 | 234 | 0.050 |
Why?
|
| Prognosis | 3 | 2020 | 5010 | 0.050 |
Why?
|
| Optic Nerve Diseases | 1 | 2004 | 85 | 0.050 |
Why?
|
| Injections | 3 | 2008 | 152 | 0.050 |
Why?
|
| Lymphoma | 1 | 2005 | 331 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 623 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 376 | 0.050 |
Why?
|
| Disease Progression | 2 | 2018 | 2227 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2023 | 283 | 0.040 |
Why?
|
| Syndrome | 2 | 2018 | 1174 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 6444 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 2164 | 0.040 |
Why?
|
| Microsporida | 1 | 2000 | 2 | 0.040 |
Why?
|
| Eye Infections, Parasitic | 1 | 2000 | 8 | 0.040 |
Why?
|
| Microsporidiosis | 1 | 2000 | 6 | 0.040 |
Why?
|
| Spinal Neoplasms | 1 | 2001 | 74 | 0.040 |
Why?
|
| Animals | 9 | 2018 | 34804 | 0.040 |
Why?
|
| Amyloidosis | 1 | 2001 | 73 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3412 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2001 | 117 | 0.040 |
Why?
|
| North America | 1 | 2020 | 265 | 0.040 |
Why?
|
| Keratitis | 1 | 2000 | 107 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2021 | 217 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 99 | 0.040 |
Why?
|
| Slit Lamp Microscopy | 1 | 2018 | 6 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 9952 | 0.040 |
Why?
|
| Nephroma, Mesoblastic | 1 | 1998 | 10 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 50 | 0.040 |
Why?
|
| Disease Management | 2 | 2016 | 563 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1710 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 327 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2018 | 75 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 113 | 0.040 |
Why?
|
| Risk Factors | 3 | 2022 | 10938 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 295 | 0.030 |
Why?
|
| Photosensitizing Agents | 1 | 2017 | 35 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2000 | 262 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2017 | 247 | 0.030 |
Why?
|
| Child | 4 | 2023 | 25763 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2016 | 52 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 131 | 0.030 |
Why?
|
| Developing Countries | 2 | 2008 | 301 | 0.030 |
Why?
|
| Polyglycolic Acid | 1 | 1995 | 23 | 0.030 |
Why?
|
| Microspheres | 1 | 1995 | 73 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 444 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 237 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 144 | 0.030 |
Why?
|
| Adenine | 1 | 2016 | 120 | 0.030 |
Why?
|
| Lactic Acid | 1 | 1995 | 153 | 0.030 |
Why?
|
| Polymers | 1 | 1995 | 108 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 801 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 1995 | 125 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2016 | 244 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 992 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 193 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 235 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1998 | 450 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 699 | 0.030 |
Why?
|
| Eye | 1 | 1995 | 235 | 0.030 |
Why?
|
| Methotrexate | 1 | 2016 | 350 | 0.030 |
Why?
|
| Heart Block | 1 | 2013 | 38 | 0.030 |
Why?
|
| Blister | 1 | 2013 | 22 | 0.030 |
Why?
|
| Bradycardia | 1 | 2013 | 60 | 0.030 |
Why?
|
| Mitomycin | 1 | 2013 | 53 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2016 | 332 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2013 | 140 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 3352 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1127 | 0.020 |
Why?
|
| Prednisone | 1 | 2013 | 253 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1305 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2013 | 142 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2013 | 128 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2016 | 418 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2013 | 125 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 128 | 0.020 |
Why?
|
| Biomarkers | 2 | 2016 | 3403 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 1177 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2005 | 249 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8542 | 0.020 |
Why?
|
| Carboplatin | 1 | 2012 | 85 | 0.020 |
Why?
|
| Etoposide | 1 | 2012 | 121 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 3993 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1011 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 136 | 0.020 |
Why?
|
| Vincristine | 1 | 2012 | 196 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1882 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 364 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2010 | 29 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 4527 | 0.020 |
Why?
|
| Adalimumab | 1 | 2008 | 25 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2008 | 156 | 0.020 |
Why?
|
| Minerals | 1 | 2008 | 58 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 160 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2008 | 92 | 0.020 |
Why?
|
| Uveitis | 1 | 2008 | 38 | 0.020 |
Why?
|
| Choroid | 1 | 2008 | 36 | 0.020 |
Why?
|
| Acetates | 1 | 2008 | 80 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 167 | 0.020 |
Why?
|
| Internationality | 1 | 2008 | 133 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2008 | 280 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 351 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 984 | 0.020 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2007 | 14 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2000 | 956 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 468 | 0.020 |
Why?
|
| Vimentin | 1 | 2007 | 69 | 0.020 |
Why?
|
| Macular Edema | 1 | 2008 | 96 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1822 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 391 | 0.020 |
Why?
|
| B-Cell CLL-Lymphoma 10 Protein | 1 | 2005 | 1 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 666 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 902 | 0.010 |
Why?
|
| Internet | 1 | 2008 | 406 | 0.010 |
Why?
|
| Neuroglia | 1 | 2007 | 213 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 552 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2193 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 4684 | 0.010 |
Why?
|
| Macrophages | 1 | 2007 | 691 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 2657 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 1300 | 0.010 |
Why?
|
| United States | 1 | 2016 | 11660 | 0.010 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2000 | 51 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 20542 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 338 | 0.010 |
Why?
|
| Inflammation | 1 | 2007 | 1519 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 442 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2000 | 200 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 3731 | 0.010 |
Why?
|
| Radiography | 1 | 2000 | 819 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 1995 | 13 | 0.010 |
Why?
|
| Ocular Physiological Phenomena | 1 | 1995 | 6 | 0.010 |
Why?
|
| Foreign-Body Reaction | 1 | 1995 | 17 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 1995 | 223 | 0.010 |
Why?
|